speb/financial-data huggingface dataset:
CURA.TO balance_sheet (annual, 2024-12-31) — Payables: 123069000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 202364000.00
CURA.TO income_statement (annual, 2024-12-31) — Pretax Income: -113358000.00
CURA.TO cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 156000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Properties: 0.00
CURA.TO cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: -347000.00
CURA.TO cash_flow (annual, 2024-12-31) — Purchase Of Business: -4699000.00
CURA.TO cash_flow (quarterly, 2024-12-31) — Purchase Of Business: 0.00
CURA.TO cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -5000000.00
CURA.TO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -708000.00
CURA.TO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -92438000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Raw Materials: 58997000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Receivables: 66482000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Receivables Adjustments Allowances: -2722000.00
CURA.TO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 617309000.00
CURA.TO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 248017000.00
CURA.TO income_statement (annual, 2024-12-31) — Rent And Landing Fees: 54105000.00
CURA.TO income_statement (annual, 2024-12-31) — Rent Expense Supplemental: 54105000.00
CURA.TO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -64561000.00
CURA.TO income_statement (annual, 2024-12-31) — Research And Development: 1421000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Restricted Cash: 14200000.00
CURA.TO balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 14200000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Retained Earnings: -1356174000.00
CURA.TO income_statement (annual, 2024-12-31) — Salaries And Wages: 253513000.00
CURA.TO cash_flow (annual, 2024-12-31) — Sale Of Business: 8487000.00
CURA.TO cash_flow (quarterly, 2024-12-31) — Sale Of Business: 4729000.00
CURA.TO cash_flow (annual, 2024-12-31) — Sale Of PPE: 1382000.00
CURA.TO income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 47075000.00
CURA.TO income_statement (annual, 2024-12-31) — Selling General And Administration: 438597000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Share Issued: 250019640.00
CURA.TO income_statement (annual, 2024-12-31) — Special Income Charges: -49364000.00
CURA.TO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 25696000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 861214000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Tangible Book Value: -853067000.00
CURA.TO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -9314970.00
CURA.TO income_statement (annual, 2024-12-31) — Tax Provision: 98251000.00
CURA.TO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (annual, 2024-12-31) — Total Assets: 2949708000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Capitalization: 1328111000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Debt: 853823000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 993393000.00
CURA.TO income_statement (annual, 2024-12-31) — Total Expenses: 1309556000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 1956315000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 2515343000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 1568390000.00
CURA.TO income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 24743000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Total Tax Payable: 38119000.00
CURA.TO income_statement (annual, 2024-12-31) — Total Unusual Items: -44357000.00
CURA.TO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -44357000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 392188000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Treasury Stock: 0.00
CURA.TO balance_sheet (quarterly, 2024-12-31) — Treasury Stock: 0.00
CURA.TO balance_sheet (annual, 2024-12-31) — Work In Process: 59995000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Working Capital: 46440000.00
CURA.TO income_statement (quarterly, 2025-03-31) — +Operating Expense: 146200000.00
CURA.TO income_statement (quarterly, 2025-03-31) — +Total Revenue: 306624000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 74432000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 62084000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -421490000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 2245275000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Asset Impairment Charge: 3695000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 2064000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 248299645.00
CURA.TO income_statement (quarterly, 2025-03-31) — Basic EPS: -0.30
CURA.TO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 107226000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 547831000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -16303000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 285409000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 121867000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 121867000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -6721000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -17319000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 45034000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Cash From Discontinued Financing Activities: 0.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Cash From Discontinued Investing Activities: -178000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Cash From Discontinued Operating Activities: -6605000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -5017000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -2096000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Income Tax Payable: 48396000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Inventory: -2680000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: 0.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -4333000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Payable: 43379000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 41283000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -1924000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Receivables: 6326000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Tax Payable: 48396000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 38672000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 1705000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Changes In Cash: 14211000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Common Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 814021000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 22073000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 151058000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 72384000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Assets: 445922000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 29082000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Debt: 43252000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 72334000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 33058000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 2268000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 316231000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -4278000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Deferred Tax: -4278000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Depreciation: 53066000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 53066000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 35382000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 53066000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 35382000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 249057088.00
CURA.TO income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.30
CURA.TO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -61063000.00
CURA.TO income_statement (quarterly, 2025-03-31) — EBIT: 8845000.00
CURA.TO income_statement (quarterly, 2025-03-31) — EBITDA: 61911000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 430000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — End Cash Position: 121867000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -6721000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Finished Goods: 103688000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 22126000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: -277000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Gain On Sale Of Ppe: -1076000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 1752000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -14017000.00
CURA.TO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 98801000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Goodwill: 631816000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 1700444000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Gross PPE: 1189113000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Gross Profit: 155566000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Impairment Of Capital Assets: 3695000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 1610000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 26723000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Insurance And Claims: 2414000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Interest Expense: 25245000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 25245000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Interest Income: 171000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 171000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 16530000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Interest Payable: 10815000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Inventory: 225227000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 1375209000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -17497000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 14335000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 19681000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 9359000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 256327000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 517936000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 774263000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 19681000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -20688000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 253472000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Minority Interest: 149079000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Minority Interests: -817000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Net Debt: 439321000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -1475000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income: -61063000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -61063000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -50053000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income Discontinuous Operations: -10193000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -61063000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -50870000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -50053000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -60246000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -226000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Interest Income: -25074000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -277000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -1007000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -1007000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -25074000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -5724000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: -939000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Net PPE: 767623000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -15877000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -886423000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Non Current Accounts Receivable: 15422000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 524000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 244500000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 524000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 242500000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Non Current Note Receivables: 3157000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 63443000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Normalized Income: -49659720.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Notes Receivable: 622000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 38429000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -2163000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Operating Income: 9366000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Operating Revenue: 306624000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 252156696.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 30859000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 43252000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 19536000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -14017000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Other Gand A: 18126000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Other Income Expense: -692000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 1068628000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 1598000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 211970000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 840000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 552000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Payable: 5318000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Properties: 356378000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Other Receivables: 5320000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Other Special Charges: -1487000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Payables: 118919000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 191303000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Pretax Income: -16400000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 10000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: -127000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Business: 0.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -226000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -277000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -16077000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Raw Materials: 62097000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Receivables: 65905000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Receivables Adjustments Allowances: -2121000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 133374000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 53066000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Rent And Landing Fees: 14214000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Rent Expense Supplemental: 14214000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -20688000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Research And Development: 335000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -1417237000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Salaries And Wages: 64047000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Sale Of Business: 0.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 200000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 11130000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 109931000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Share Issued: 252156696.00
CURA.TO income_statement (quarterly, 2025-03-31) — Special Income Charges: -3284000.00
CURA.TO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 4624000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 814021000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -886423000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -321720.00
CURA.TO income_statement (quarterly, 2025-03-31) — Tax Provision: 33653000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Assets: 2947427000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 1331957000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Debt: 846597000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 963100000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Total Expenses: 297258000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 1984327000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 2501505000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1668096000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 9366000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 39169000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Total Unusual Items: -1532000.00
CURA.TO income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -1532000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 437363000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Work In Process: 59442000.00
CURA.TO balance_sheet (quarterly, 2025-03-31) — Working Capital: 129691000.00
CURA.TO income_statement (quarterly, 2025-06-30) — +Operating Expense: 149268000.00
CURA.TO income_statement (quarterly, 2025-06-30) — +Total Revenue: 314520000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 66271000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 67141000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -447046000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 2342112000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Asset Impairment Charge: -1209000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Assets Held For Sale Current: 2964000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 252423544.00
CURA.TO income_statement (quarterly, 2025-06-30) — Basic EPS: -0.24
CURA.TO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 121867000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 552155000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -15386000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 282014000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 102269000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 102269000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -12102000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -16450000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 6075000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Cash From Discontinued Financing Activities: 0.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Cash From Discontinued Investing Activities: 178000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Cash From Discontinued Operating Activities: 2441000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -9015000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 70120000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Inventory: 42000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: -723000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -4418000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Payable: -57411000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 12709000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 4124000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Receivables: -4241000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 7493000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -3925000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -19858000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Common Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 871297000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 17974000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 161967000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 68602000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Assets: 430255000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 30034000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Debt: 48729000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 78763000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 29927000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 1754000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 293069000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -8149000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Deferred Tax: -8149000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Depreciation: 55931000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 55931000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 35574000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 55931000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 35574000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 252423544.00
CURA.TO income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.24
CURA.TO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -65022000.00
CURA.TO income_statement (quarterly, 2025-06-30) — EBIT: 6499000.00
CURA.TO income_statement (quarterly, 2025-06-30) — EBITDA: 62430000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Earnings From Equity Interest Net Of Tax: -11861000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 260000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — End Cash Position: 102269000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -12102000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Finished Goods: 95330000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -6870000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: -53000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Ppe: -253000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 3503000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -419000.00
CURA.TO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 101008000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Goodwill: 635507000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 1695809000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 67141000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 1204072000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Gross Profit: 152553000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: -1209000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 19302000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 14142000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Insurance And Claims: 2262000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Interest Expense: 25720000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 25720000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Interest Income: 166000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 166000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 34962000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Interest Payable: 2187000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Inventory: 226534000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 1432299000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -16272000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 15188000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 16702000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Land And Improvements: 9388000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 251980000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 512273000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 764253000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Long Term Debt Issuance: 16702000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -21181000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 265366000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Minority Interest: 63962000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Minority Interests: 445000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -542000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Net Debt: 458733000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: -3449000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income: -65022000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -65022000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -62463000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income Discontinuous Operations: -3004000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -65022000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -62018000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -55342000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -65467000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -159000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Interest Income: -25554000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -10000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -4479000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -4479000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -25554000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -7623000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: -557000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Net PPE: 757026000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -15182000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -824512000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Non Current Accounts Receivable: 15738000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 576000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 237141000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 576000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 234156000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Non Current Note Receivables: 2215000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 57971000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Normalized Income: -65540610.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Notes Receivable: 2146000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 8516000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -3249000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Operating Income: 3285000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Operating Revenue: 314520000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 254806930.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 26378000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 48729000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 15415000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -419000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Other Gand A: 19363000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Other Income Expense: 3048000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 1060302000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 1839000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 210185000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -1411000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 973000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Payable: 9382000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Properties: 359189000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Other Receivables: 4219000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Payables: 100362000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 168964000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Pretax Income: -19221000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 0.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Provisionand Write Offof Assets: 284000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -542000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -159000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -10000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -15227000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Raw Materials: 73136000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Receivables: 72110000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Receivables Adjustments Allowances: -1396000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 141610000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 55931000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Rent And Landing Fees: 15742000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Rent Expense Supplemental: 15742000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -21181000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Research And Development: 257000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -1470396000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 63641000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Sale Of Business: 0.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 45000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 11456000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 112464000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Share Issued: 254806930.00
CURA.TO income_statement (quarterly, 2025-06-30) — Special Income Charges: 956000.00
CURA.TO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 8477000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 871297000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -824512000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 936390.00
CURA.TO income_statement (quarterly, 2025-06-30) — Tax Provision: 31381000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Assets: 2916807000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 1383570000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Debt: 843016000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 935259000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Total Expenses: 311235000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 1981548000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 2486552000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 1688479000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 3285000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 24709000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items: 4459000.00
CURA.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 4459000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Tradeand Other Payables Non Current: 476900000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Work In Process: 58068000.00
CURA.TO balance_sheet (quarterly, 2025-06-30) — Working Capital: 137186000.00
CURA.TO income_statement (quarterly, 2025-09-30) — +Operating Expense: 155710000.00
CURA.TO income_statement (quarterly, 2025-09-30) — +Total Revenue: 320244000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 54016000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 67375000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -468500000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 2344461000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 2219000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 4284000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 254941873.00
CURA.TO income_statement (quarterly, 2025-09-30) — Basic EPS: -0.24
CURA.TO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 102269000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 551599000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -16592000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 279717000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 92788000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 92788000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -25728000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -17267000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 52881000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Cash From Discontinued Financing Activities: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Cash From Discontinued Investing Activities: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Cash From Discontinued Operating Activities: -4443000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -11931000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 57432000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Inventory: -1930000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 1817000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -4459000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Payable: -11931000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 45501000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -573000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Receivables: -669000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 39687000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -669000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Changes In Cash: 5443000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Common Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 814824000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 18117000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 160503000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 82719000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Assets: 440048000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 30666000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Debt: 43693000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 74359000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 29812000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 856000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 299034000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -4660000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Deferred Tax: -4660000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Depreciation: 54372000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 54372000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 35239000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 54372000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 35239000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 254941873.00
CURA.TO income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.24
CURA.TO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -57029000.00
CURA.TO income_statement (quarterly, 2025-09-30) — EBIT: 1057000.00
CURA.TO income_statement (quarterly, 2025-09-30) — EBITDA: 55429000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -224000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — End Cash Position: 107488000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -25728000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Finished Goods: 105341000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 31846000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: 1423000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: -1221000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -2584000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -2210000.00
CURA.TO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 104174000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Goodwill: 634995000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 1668423000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Gross PPE: 1211082000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Gross Profit: 159741000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 848000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 6515000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 19908000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Insurance And Claims: 2317000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Interest Expense: 25365000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 25365000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Interest Income: 151000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 151000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 17381000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Interest Payable: 11085000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Inventory: 229123000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 1358481000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -17267000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 1373000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 3146000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Land And Improvements: 9368000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 249051000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 499964000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 749015000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: 3146000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -28840000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 1373000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 268316000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Minority Interest: 71406000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Minority Interests: -345000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Net Debt: 450869000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: 1160000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income: -57029000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -57029000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -54546000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income Discontinuous Operations: -2138000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -57029000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -54891000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -54548000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -56684000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -35000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Interest Income: -25214000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -25694000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -25694000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -25214000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -237000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -1291000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Net PPE: 742582000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -16106000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -853599000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Accounts Receivable: 15738000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 486000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 229019000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 486000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 229019000.00